ASH2023注目テーマ⑬ 注目演題「#1051」

Lovo-celにより鎌状赤血球症患者の
血管閉塞性イベントが消失
Hb機能正常化は長期持続 Efficacy, Safety, and Health-Related Quality of Life (HRQOL) in Patients with Sickle Cell Disease (SCD) Who Have Received Lovotibeglogene Autotemcel (Lovo-cel) Gene Therapy: Up to 60 Months of Follow-up (#1051)

Julie Kanter, MD（Division of Hematology and Oncology, University of Alabama, Birmingham, USA）